Author: sugaradmin

Introduction and Objective: With the approval of teplizumab for stage 2 type 1 diabetes (T1D), widespread islet autoantibody (IA) screening is increasingly important. We estimated the size of groups at higher risk for T1D and projected IA positivity rates within the UCSF electronic medical record (EMR).Methods: Using de-identified EMR data, we identified patients of all […]

Introduction and Objective: Treatment with SGLT-2i reduces the risk of both cardiovascular and renal outcomes in type 2 diabetes (T2D). Recent findings indicate that in obese individuals, the kidney exhibits lower 18Fluorodeoxyglucose ([18F]-FDG) uptake rates compared to lean individuals, possibly due to insulin resistance. This study aims to evaluate changes in renal [18F]-FDG uptake in […]

Introduction and Objective: This study analyzes trends in Type 1 diabetes mellitus (T1DM) incidence, prevalence, mortality, and disability-adjusted life years (DALYs) in China from 1990 to 2021, with projections through 2036.Methods: Data from the GBD 2021 study were used to calculate annual changes in age-standardized rates (ASRs) for T1DM via joinpoint regression. Age-period-cohort analysis assessed […]

Introduction and Objective: Glycemic variability (GV) is associated with poor glycemic control and complications in patients with T2DM. The coefficient of variation (CV) derived from CGM has been widely used as a reliable measure of GV.Methods: A total of 773 patients with T2DM were included. A multivariate linear regression model was used to assess independent […]

Introduction and Objective: DKA at the time of first presentation of T1DM is preventable. The aim of this study was to determine the proportion of individuals with a new onset T1DM, by race and ethnicity, presenting with DKA in a large integrated healthcare system based in Northern California (Sutter Health).Methods: ICD-9 and ICD-10 codes were […]

Introduction and Objective: CGMs help millions of people manage their diabetes. These use passive sensors that have performance and usability limitations. IMS uses semiconductor and nano technologies to create a highly miniaturized electrochemical sensor, the CGM+. It uses a multi-sensor array and sends multiplexed data to an external transmitter, which processes and relays it to […]

Introduction and Objective: Effective diabetes management often relies on the use of advanced technologies such as continuous glucose monitoring (CGM) systems and insulin pumps. However, barriers to accessing and utilizing these tools can significantly hinder individuals with type 1 diabetes (T1D). To explore these challenges, we conducted focus groups and structured interviews with a diverse […]

Introduction and Objective: Prior work by the Michigan Collaborative for Type 2 Diabetes (MCT2D) demonstrated increased adherence to non-insulin guideline-directed medical therapy (NI-GDMT) for type 2 diabetes (T2D) over the past 4 years but insulin use remains unclear. We examined insulin use in MCT2D practices over this period.Methods: We analyzed pharmacy claims from 82,207 adults […]

Introduction and Objective: To investigate the prevalence of overweight or obesity among persons with type 1 diabetes (T1D) globally.Methods: Multiple databases were searched for observational studies reporting the prevalence of overweight or obesity in persons with T1D from the inception to March 2024. The pooled prevalences of overweight or obesity were calculated according to the […]

Introduction and Objective: The Stelo Glucose Biosensor offers real-time glucose data and insights to individuals not on insulin, with or without diabetes. This study assessed early user experiences to evaluate the impact of real-time glucose monitoring on glycemic outcomes and behavior in users with no diabetes (ND), prediabetes (PreD), or Type 2 Diabetes (T2D) during […]